DIR Return Create A Forum - Home
       ---------------------------------------------------------
       MS Speaks
  HTML https://msspeaks.createaforum.com
       ---------------------------------------------------------
       *****************************************************
   DIR Return to: TYSABRI (natalizumab)
       *****************************************************
       #Post#: 1357--------------------------------------------------
       (Abst.) Predictors of severity and functional outcome in
       Tysabri-associated PML
   DIR By: agate
       Date: September 12, 2016, 10:46 pm
       ---------------------------------------------------------
       From PubMed, September 8, 2016:
       --- Quote ---
       > Mult Scler. 2016 Sep 6.
       > Predictors of severity and functional outcome in
       natalizumab-associated progressive multifocal
       leukoencephalopathy
       >
       > Hoepner R1, Kolb EM2, Dahlhaus S3, Hellwig K2, Adams O4,
       Kleiter I2, Salmen A5, Schneider R2, Lukas C6, Chan A5, Berger
       JR7, Gold R2.
       >
       > Author information
       >
       > 1Department of Neurology, St. Josef Hospital, Ruhr University
       Bochum, Bochum, Germany roberthoepner@gmx.de.
       > 2Department of Neurology, St. Josef Hospital, Ruhr University
       Bochum, Bochum, Germany.
       > 3Department of Neurology, Alfried Krupp Hospital, Essen,
       Germany.
       > 4Department of Virology, Heinrich Heine University,
       Düsseldorf, Germany.
       > 5Department of Neurology, St. Josef Hospital, Ruhr University
       Bochum, Bochum, Germany/Department of Neurology, University
       Hospital Bern and University of Bern, Bern, Switzerland.
       > 6Department of Radiology, St. Josef Hospital, Ruhr University
       Bochum, Bochum, Germany.
       > 7Department of Neurology, University of Pennsylvania,
       Philadelphia, PA, USA.
       >
       > OBJECTIVE:
       >
       > Progressive multifocal leukoencephalopathy (PML) is an
       emerging complication of immunosuppressive therapies, especially
       natalizumab in multiple sclerosis (MS). Factors associated with
       functional outcome of natalizumab-associated PML
       (natalizumab-PML) have not been sufficiently described.
       >
       > METHODS:
       >
       > We retrospectively analyzed medical records of all patients
       with natalizumab-PML (n = 32) treated in our
       hospital since 2009. Disability measured by Expanded Disability
       Status Scale (EDSS) at two different time points (highest
       available EDSS during PML and last available EDSS after PML
       diagnosis) served as functional outcome parameters. Clinical,
       laboratory, and imaging data were analyzed for association with
       functional outcome by applying Spearman's rho and multivariate
       regression analysis.
       >
       > RESULTS:
       >
       > In all, 31/32 patients survived PML. A poor functional outcome
       was associated with higher age, higher initial John Cunningham
       virus (JCV) copy number in cerebrospinal fluid (CSF), and more
       extensive PML lesions on initial magnetic resonance imaging
       (MRI). No association between functional outcome and the
       duration of natalizumab therapy or a delayed PML diagnosis was
       observed.
       >
       > CONCLUSION:
       >
       > This study will be useful for neurological practice to
       estimate functional outcome or disease severity of
       natalizumab-PML in primary care settings.
       --- End Quote ---
  HTML http://www.ncbi.nlm.nih.gov/pubmed/27600113
  HTML http://www.ncbi.nlm.nih.gov/pubmed/27600113
       *****************************************************
       Page 1 of 1